Drugs / TAS4464
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02978235 | Mar 2017 → Feb 2018 | non-Hodgkin lymphoma, plasma cell myeloma | Taiho Oncology, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS4464 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02978235 ↗ |
| Action | Inhibit | “TAS4464 is an investigational NEDD8 activating enzyme (NAE) inhibitor” NCT02978235 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT02978235 ↗ |